First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination

First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination

Hepatocellular carcinoma (HCC) is an aggressive malignancy accounting for 90% of primary liver malignancies. Therapeutic options for HCC are primarily based on the baseline functional status, the extent of disease at presentation and the underlying liver function that is clinically evaluated by the...

書目詳細資料
Main Authors:	Sri Harsha Tella, Anuhya Kommalapati, Amit Mahipal, Zhaohui Jin
格式:	Article
語言:	English
出版:	MDPI AG 2022-06-01
叢編:	Biomedicines
主題:	liver cancer immunotherapy atezolizumab bevacizumab nivolumab
在線閱讀:	https://www.mdpi.com/2227-9059/10/6/1304

相似書籍

A case of nearly complete response in hepatocellular carcinoma with disseminated lung metastasis by combination therapy of nivolumab and ipilimumab after treatment failure of atezolizumab plus bevacizumab
由: Hyung Jun Kim, et al.
出版: (2023-03-01)

Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports
由: Ali AL Zahrani, et al.
出版: (2021-03-01)

Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma
由: Parissa Tabrizian, et al.
出版: (2025-02-01)

Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial
由: Sun Young Yim, et al.
出版: (2024-10-01)

High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma
由: Hannah Yang, et al.
出版: (2023-04-01)

Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma
由: Tomoyuki Satake, et al.
出版: (2023-07-01)

Safety and Efficacy of Concurrent Atezolizumab/Bevacizumab or Nivolumab Combination Therapy with Yttrium-90 Radioembolization of Advanced Unresectable Hepatocellular Carcinoma
由: Alexander Villalobos, et al.
出版: (2023-11-01)

Safety and Efficacy of Atezolizumab and Bevacizumab Combination as a First Line Treatment of Advanced Hepatocellular Carcinoma
由: Zanuso V, et al.
出版: (2023-10-01)

Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?
由: Francesco Tovoli, et al.
出版: (2020-10-01)

Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice
由: Sae Yumita, et al.
出版: (2023-03-01)

Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve
由: Tetsu Tomonari, et al.
出版: (2023-02-01)

Letter regarding “Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab”
由: Sun Hyun Bae, et al.
出版: (2023-09-01)

Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab
由: Tae Hyun Kim, et al.
出版: (2023-09-01)

Effect of butyrate‐producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab
由: Kazuhiro Nouso, et al.
出版: (2023-09-01)

Thyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma
由: Young Shin Song, et al.
出版: (2023-05-01)

Preliminary results of retrospective analysis Atezolizumab and Bevacizumab in first-line therapy of advanced HCC
由: I. А. Dzhanyan, et al.
出版: (2021-06-01)

Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma
由: Hideki Iwamoto, et al.
出版: (2022-07-01)

Efficacy of Atezolizumab Plus Bevacizumab–Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma
由: Etsuko Moriyama, et al.
出版: (2024-09-01)

Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study
由: Young Eun Chon, et al.
出版: (2024-07-01)

Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first‐line treatment for unresectable hepatocellular carcinoma
由: Chung‐Wei Su, et al.
出版: (2023-03-01)

Comparison of the prognostic effect of sarcopenia on atezolizumab plus bevacizumab and lenvatinib therapy in hepatocellular carcinoma patients
由: Katsuya Toshida, et al.
出版: (2022-07-01)

Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy
由: Ryosuke Tsunemitsu, et al.
出版: (2023-06-01)

Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy
由: Masatoshi Kudo
出版: (2021-02-01)

Case Report: Successful liver transplantation after achieving complete clinical remission of advanced HCC with Atezolizumab plus Bevacizumab combination therapy
由: Yasmina Chouik, et al.
出版: (2023-06-01)

A Case of Immune-Related Aseptic Meningitis during Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma
由: Hiroki Kawanaka, et al.
出版: (2024-01-01)

Efficacy and safety of atezolizumab–bevacizumab vs pembrolizumab-lenvatinib in unresectable hepatocellular carcinoma: a retrospective, cohort study
由: Zili Hu, et al.
出版: (2024-11-01)

Efficacy of Atezolizumab Plus Bevacizumab Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Real-World Study
由: Shen X, et al.
出版: (2024-10-01)

Atezolizumab plus bevacizumab-induced intratumoral hemorrhage in a patient with rib metastasis from unresectable hepatocellular carcinoma
由: Yasuhito Mitsuyama, MD, et al.
出版: (2023-09-01)

Favorable response of hepatocellular carcinoma with portal vein tumor thrombosis after radiotherapy combined with atezolizumab plus bevacizumab
由: Yong Tae Kim, et al.
出版: (2023-03-01)

Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3‐year survival update and multi‐omics analysis
由: Jie Dai, et al.
出版: (2025-01-01)

The prediction of early progressive disease in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab
由: Yasuto Takeuchi, et al.
出版: (2023-09-01)

Clinical case of long-term use of atezolizumab and bevacizumab in the first-line treatment of recurrence of non-small cell lung cancer
由: O. A. Rozonova, et al.
出版: (2020-07-01)

Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab
由: Meng Wu, et al.
出版: (2025-02-01)

Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab
由: Margherita Rimini, et al.
出版: (2024-08-01)

Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination
由: Takahiro Niimura, et al.
出版: (2023-08-01)

Frontline evaluation: Atezolizumab–bevacizumab versus lenvatinib for BCLC stage B hepatocellular carcinoma exceeding the up‐to‐seven criteria
由: Masamichi Kimura, et al.
出版: (2024-09-01)

Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib
由: Atsushi Hiraoka, et al.
出版: (2023-01-01)

The impact of curative conversion therapy aimed at a cancer‐free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
由: Shigeo Shimose, et al.
出版: (2023-06-01)

A case of successful surgical treatment for peritoneal seeding of hepatocellular carcinoma after radiotherapy and atezolizumab plus bevacizumab combination treatment
由: Yuri Cho, et al.
出版: (2023-03-01)

Complete response in hepatocellular carcinoma with lymph node metastasis by combination therapy of atezolizumab and bevacizumab: a case report
由: Sang Youn Hwang, et al.
出版: (2021-09-01)